• Explore /
  • Poster
  • / ERA 223: A phase 3 trial of radium-223 dichloride in combination with abiraterone acetate and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone-predominant metastatic castration-resistant prostate cancer.

ERA 223: A phase 3 trial of radium-223 dichloride in combination with abiraterone acetate and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone-predominant metastatic castration-resistant prostate cancer.

Abstract Poster

Authors

null

Matthew R. Smith

Massachusetts General Hospital, Boston, MA

Matthew R. Smith , Chris C. Parker , Bertrand F. Tombal , Kurt Miller , Fred Saad , JunWu Shen , Amily Zhang , Martin Kornacker , Celestia S. Higano

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02043678

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS5088)

DOI

10.1200/JCO.2016.34.15_suppl.TPS5088

Abstract #

TPS5088

Poster Bd #

437b

Abstract Disclosures

Similar Posters

First Author: Matthew Raymond Smith

First Author: Johann S. De Bono

First Author: Simon J. Crabb

First Author: Yuchao Ni